<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-9M07PJTO/34554459-9afb-43bf-b82a-8cdee77f4183/PDF"><dcterms:extent>1153 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-9M07PJTO/6848bc2f-a3ab-4753-8413-e38df2b0ca05/TEXT"><dcterms:extent>42 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2005-2025"><edm:begin xml:lang="en">2005</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-9M07PJTO"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN" /><dcterms:issued>2025</dcterms:issued><dc:creator>Knez, Damijan</dc:creator><dc:creator>Kocbek, Petra</dc:creator><dc:creator>Kralj, Slavko</dc:creator><dc:creator>Nemec, Sebastjan</dc:creator><dc:format xml:lang="sl">številka:1</dc:format><dc:format xml:lang="sl">letnik:76</dc:format><dc:format xml:lang="sl">str. 30-38</dc:format><dc:identifier>COBISSID_HOST:230471683</dc:identifier><dc:identifier>ISSN:2536-4316</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-9M07PJTO</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko farmacevtsko društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Farmacevtski vestnik</dcterms:isPartOf><dc:subject xml:lang="sl">Alzheimerjeva bolezen</dc:subject><dc:subject xml:lang="sl">amolid beta</dc:subject><dc:subject xml:lang="en">amyloid beta</dc:subject><dc:subject xml:lang="sl">Nanodelci</dc:subject><dc:subject xml:lang="sl">Nanotehnologija</dc:subject><dc:subject xml:lang="sl">protein tau</dc:subject><dc:subject xml:lang="en">tau protein</dc:subject><dcterms:temporal rdf:resource="2005-2025" /><dc:title xml:lang="sl">Nanotehnološki pristopi za zdravljenje Alzheimerjeve bolezni| Nanotechnology-based approaches for the treatment of Alzheimer’s disease|</dc:title><dc:description xml:lang="sl">Alzheimer’s disease is an incurable neurodegenerative disease characterized by the degeneration of neurons and the deterioration of cognitive functions. The currently approved drugs primarily address the symptoms of the disease and potential new drugs have been relatively unsuccessful in clinical trials. Due to the failure of these new agents, new approaches to treating Alzheimer’s disease have come to the forefront of research, including approaches from the field of nanotechnology. There is already a number of studies where the effect of mainly polymer, gold, and iron oxide nanoparticles in preventing the self-aggregation of amyloid ß monomers and tau protein is investigated. In addition, these nanoparticles are also being investigated for their ability to disaggregate already formed aggregates of amyloid ß and tau protein. The available research provides a baseline for further investigation of nano - technological processes for the development of new treatment options for various diseases, in addition to Alzheimer’s, that are associated with pathological protein aggregation</dc:description><dc:description xml:lang="sl">Alzheimerjeva bolezen je neozdravljiva nevrodegenerativna bolezen, za katero je značilno propadanje živčnih celic in izguba kognitivnih funkcij. Trenutno odobrena zdravila naslavljajo predvsem simptome bolezni. številne nove potencialne zdravilne učinkovine, ki vplivajo tudi na potek bolezni, pa so se v kliničnih raziskavah izkazale kot sorazmerno ne - uspešne. S tem razlogom v središče raziskav prihajajo novi pristopi zdravljenja Alzheimerjeve bolezni, ki temeljijo na uporabi nanotehnologije. Izvedena je bila že vrsta raziskav, v katerih so proučevali vplive različnih nanodelcev na tarče, povezane z nastankom in razvojem te bolezni. Proučevali so učinke polimernih nanodelcev, nanodelcev zlata ter železovega oksida na samozdruževanje monomerov amiloida ß in proteina tau v agregate, kot tudi uporabo omenjenih nanodelcev za razgradnjo že nastalih agregatov proteinov. Izsledki teh raziskav predstavljajo pomembno izhodišče za nadaljnje raziskave in razvoj nanotehnoloških pristopov za razgradnjo agregiranih proteinskih struktur in razvoj novih možnosti zdravljenja različnih bolezni, ki jih povezujemo s patološkim nastajanjem proteinskih agregatov</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-9M07PJTO"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-9M07PJTO" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-9M07PJTO/34554459-9afb-43bf-b82a-8cdee77f4183/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by-nc/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko farmacevtsko društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-9M07PJTO/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-9M07PJTO" /></ore:Aggregation></rdf:RDF>